Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,775.00
Bid: 1,700.00
Ask: 1,779.00
Change: 0.00 (0.00%)
Spread: 79.00 (4.647%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 1,775.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON BRIEFING: Games Workshop seals Amazon deal for Warhammer 40,000

Mon, 18th Dec 2023 07:55

(Alliance News) - Stocks in London were set to retreat slightly on Monday, in line with equity markets in Asia, at the start of the last week before the Christmas holidays.

Last week saw a rally in stock markets across the globe, thanks to a dovish pivot from the US Federal Reserve, though the FTSE 100 underperformed somewhat. This week, investors will be keeping a close eye on Friday's US personal consumption expenditures price index data - the Fed's preferred metric of inflation.

Another key focal point for the week will be the Bank of Japan's monetary policy decision to be announced on Tuesday.

"There is nothing more than a slim probability for the BoJ to exit negative rates this week, but investors are eager to hear further details about how and when the BoJ will leave the negative rate territory," said Swissquote Bank senior analyst Ipek Ozkardeskaya.

Here is what you need to know at the London market open:

----------

MARKETS

----------

FTSE 100: called down 10.4 points, 0.1%, at 7,561.96

----------

Hang Seng: down 1.1% at 16,612.95

Nikkei 225: closed up 0.6% at 32,758.98

S&P/ASX 200: closed down 0.2% at 7,426.40

----------

DJIA: closed up 0.2%, at 37,305.16

S&P 500: closed little changed at 4,719.19

Nasdaq Composite: closed up 0.4% at 14,813.92

----------

EUR: up at USD1.0919 (USD1.0912)

GBP: down at USD1.2689 (USD1.2693)

USD: up at JPY142.26 (JPY141.75)

GOLD: down at USD2,023.33 per ounce (USD2,034.62)

OIL (Brent): up at USD77.31 a barrel (USD76.34)

(changes since previous London equities close)

----------

ECONOMICS

----------

Monday's key economic events still to come:

10:00 CET Germany Ifo business climate index

09:30 GMT UK card spending statistics

10:00 EST US NAHB housing market index

----------

BROKER RATING CHANGES

----------

Morgan Stanley cuts Fresnillo to 'underweight' (equal-weight) - price target to 540 (620) pence

----------

UBS cuts Barratt Developments to 'neutral' (buy) - price target 610 (495) pence

----------

UBS raises Taylor Wimpey to 'buy' (neutral) - price target 160 (126) pence

----------

COMPANIES - FTSE 100

----------

Spirax-Sarco Engineering named Louisa Burdett as its new chief financial officer, with a starting date of July next year. Burdett is currently CFO at Croda International, and has led finance functions at "several large companies" including Meggitt and Victrex. Spirax-Sarco said CFO Nimesh Patel, who was previously announced to be its new CEO, will take the helm of the firm on January 16. Group finance director, Phil Scott, will be interim CFO from that date until Burdett joins the company. Croda International noted Burdett's departure, and said it has begun the search for her successor. Additionally, Croda said adjusted pretax profit was likely to come at the lower end of its guidance of GBP300 million to GBP320 million range, mostly due to recent currency movements, especially in Argentina.

----------

GSK announced positive headline results from the second part of its phase III trial of Jemperli plus standard-of-care chemotherapy, followed by dostarlimab plus Zejula as maintenance therapy, in adult patients with primary advanced or recurrent endometrial cancer. "The trial, which evaluated this combination against placebo plus chemotherapy followed by placebo, met its primary endpoint of progression-free survival, with a statistically significant and clinically meaningful benefit observed in both the overall patient population and in a subpopulation of patients with mismatch repair proficient/microsatellite stable tumours," GSK explained.

----------

The Financial Times reported that GSK is looking for some new deals in China. This comes after GSK rebuilt a "very strong" relationship with the government and local companies since a corruption scandal a decade ago, the newspaper said. Chief Commercial Officer Luke Miels told the FT that GSK is working on further deals with Chinese companies after it signed a licensing agreement in October worth up to USD1.5 billion for a cancer drug developed by Hansoh Pharmaceutical Group.

----------

Frasers Group is in talks to buy Matchesfashion, a luxury clothing retailer, from its private equity owner since 2017, Apax Partners, Sky News reported on Saturday. Citing "City sources", Sky said Frasers is among a small group of bidders that submitted offers early last week. Frasers would likely pay in excess of GBP50 million for Matchesfashion, whose business has struggled, according to Sky, citing an "insider". Sky said fellow London-listed retailer Next also is said to have expressed an interest in buying Matchesfashion.

----------

COMPANIES - FTSE 250

----------

Games Workshop has entered an agreement with Amazon's Content Services subsidiary for the prospective development of its Warhammer 40,000 universe into films and television series, alongside the associated merchandising rights. The deal grants exclusive rights to Amazon for film and TV series set within the universe, as well as an option for exclusive rights in the Warhammer Fantasy universe down the line. "Games Workshop and Amazon will work together for a period of 12 months to agree creative guidelines for the films and television series to be developed by Amazon. The agreement will only proceed once the creative guidelines are mutually agreed between Games Workshop and Amazon," the UK company said. It added that it will make no change to its forecast for its financial year ending in June. Games Workshop had announce an agreement in principle with Amazon in December last year.

----------

IP Group has launched a share buy back for up to GBP20 million. The intellectual property investor said the programme came in light of the discount of its share price to its net asset value per share, and it determined now to be "an appropriate time".

----------

OTHER COMPANIES

----------

Hollywood Bowl held its annual dividend unchanged and announced plans for a share buyback worth up to GBP10 million. The operator of ten-pin bowling centres reported pretax profit of GBP45.1 million for the financial year that ended September 30, down from GBP46.7 million in financial 2022, which benefited from a reduced rate of value-added tax on bowling.

----------

Canadian Overseas Petroleum said its non-binding Cole Creek joint venture letter of intent has been terminated, and it plans "no further discussions at this stage". Back in July, COPL had announced the potential joint venture with "an established energy company" to develop and exploit oil reserves at the Cole Creek in Converse and Natrona counties, Wyoming. "The company will provide a further update before year end regarding its strategy relating to the development of its Cole Creek and Barron Flats Shannon Units," COPL said on Monday.

----------

By Elizabeth Winter, Alliance News deputy news editor

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
17 Jan 2024 07:46

LONDON BRIEFING: UK inflation surprises as unexpectedly rises to 4.0%

(Alliance News) - Stocks in London are called to open lower on Wednesday, following some hotter-than-expected consumer price data from the UK.

Read more
17 Jan 2024 07:31

GSK raises $1.24 bln from latest Haleon stake sale

Jan 17 (Reuters) - GSK has raised 978 million pounds ($1.24 billion) from a discounted sale of a stake in its spun-off consumer healthcare business Haleon, the British drugmaker said on Wednesday.

Read more
16 Jan 2024 17:04

GSK to sell GBP1 billion worth of Haleon shares as trims stake again

(Alliance News) - GSK PLC on Tuesday said it intends to sell around GBP1.00 billion worth of shares in Haleon PLC, as it continues to reduce its shareholding in the Weybridge, Surrey-based consumer healthcare spin-off.

Read more
16 Jan 2024 09:14

LONDON BROKER RATINGS: UBS raises GSK and cuts AstraZeneca

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
16 Jan 2024 08:15

UBS downgrades AstraZeneca to 'sell'

(Sharecast News) - UBS has downgraded AstraZeneca and upgraded rival GSK as part of its latest review of the European pharmaceutical sector.

Read more
16 Jan 2024 07:37

LONDON BRIEFING: UK jobless rate sticks at 4.2% but pay growth slows

(Alliance News) - Stocks in London are called to open lower on Tuesday, following data showing that the UK jobless rate was unchanged at 4.2% as pay growth slowed.

Read more
15 Jan 2024 08:42

Zantac fallout unfairly weighing on GSK, says Shore Capital

(Sharecast News) - Shore Capital has raised its target price and maintained a positive stance on biopharma giant GSK, saying that worries about the potential cost of Zantac litigation are unfairly weighing on the stock.

Read more
10 Jan 2024 09:35

LONDON BROKER RATINGS: BofA cuts Ashtead; UBS likes 3i Group

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
10 Jan 2024 08:25

GSK says Nucala gets green light in China for asthma treatment

(Alliance News) - GSK PLC on Wednesday said Nucala has been approved in China for the treatment of severe asthma.

Read more
10 Jan 2024 07:22

GSK's Nucala gets fresh approval in China

(Sharecast News) - GSK announced on Wednesday that the China National Medical Products Administration (NMPA) has granted approval for 'Nucala', or mepolizumab, as an add-on maintenance treatment for severe eosinophilic asthma in adults and adolescents aged 12 years and older.

Read more
9 Jan 2024 16:22

London close: Stocks finish red after choppy session

(Sharecast News) - London stocks had turned back into the red by the close on Tuesday, with recruitment firms and asset managers pacing the declines after some disappointing corporate updates.

Read more
9 Jan 2024 08:03

TOP NEWS: GSK to buy Aiolos Bio for up to USD1.4 billion

(Alliance News) - GSK PLC on Tuesday said it will acquire asthma drug developer Aiolos Bio Inc for USD1 billion upfront, as well as up to USD400 million in certain success-based milestone payments.

Read more
9 Jan 2024 07:16

GSK buys respiratory drug maker Aiolos for $1bn

(Sharecast News) - GSK said it was buying Aiolos, a clinical-stage biopharmaceutical company focused on treatment of respiratory and inflammatory conditions, for up to $1.4bn (£1.1bn).

Read more
8 Jan 2024 23:39

Pfizer to remain aggressive on obesity market after setback

NEW YORK, Jan 8 (Reuters) - Pfizer will remain aggressive in trying to break into the lucrative obesity market, even after dropping a high profile weight-loss drug candidate late last year due to strong side effects, Chief Executive Albert Bourla said on Monday.

Read more
8 Jan 2024 23:00

Pfizer to remain aggressive on obesity market after setback

NEW YORK, Jan 8 (Reuters) - Pfizer will remain aggressive in trying to break into the lucrative obesity market, even after dropping a high profile weight-loss drug candidate late last year due to strong side effects, Chief Executive Albert Bourla said on Monday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.